XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
XOMA (XOMA) Target Cut to $9 at Jefferies
March 5, 2014 8:37 AM ESTJefferies analyst Biren Amin cut is price target on XOMA, Ltd. (NASDAQ: XOMA) from $11 to $9 after the company announced that the gevokizumab program for erosive osteoarthritis of the hand (EOA) is being discontinued after gevokizumab failed to demonstrate benefit in the two PII trials. The... More
XOMA (XOMA) Sinks Over 15% on Trade Resumption
March 4, 2014 5:29 PM ESTXOMA (NASDAQ: XOMA) has resumed trading and is down 15.2% after reporting that it will not purse gevokizumab development for the broad EOA indication. In addition, XOMA reported a large fourth quarter loss.... More
XOMA Ltd (XOMA) Posts Q4 GAAP Loss of 55c/Share
March 4, 2014 5:00 PM ESTXOMA Ltd (NASDAQ: XOMA) reported Q4 EPS of ($0.55), which may not compare with the analyst estimate of ($0.19). Revenue for the quarter came in at $8.45 million versus the consensus estimate of $7.92 million.
Of the $0.55 per share loss, $35.3 million, or $0.37 per share, was related directly to the... More
